110 likes | 233 Vues
This document provides an update on the Laboratory Results Interface (LRI) Pilot Projects, emphasizing participation from major vendors like Allscripts, Cerner, and Atlas Development. It outlines the progression of test messages within Phase 1 and 2 involving various laboratory tests, including anatomical pathology and toxicology. Emphasis is placed on collaborator coordination and validation suite preparations leading to a robust support framework for EHR and lab systems integrations. Steps for future participation in Pilot II and related communications are also detailed.
E N D
LRI/LOI Pilots May 1, 2012
Participants Pilot I Project Participants • Allscripts • Atlas Development • CAP • Cerner • Halfpenny Technologies • KHIE • LabLynx • RML Coordination of Effort • Validation Suite • Vocabulary Group • Implementation Guide Analysis • Support Team • Others Pilot II Project Participants Conversations • Lab System and EHR Vendor (2) • Lab System Vendor (1) • EHR Vendor (3) • Commercial Laboratories (2) • Provider Based Commercial Labs (3) Pilot I Project Participants • Allscripts • Cerner • Optimum Insight • RML
LRI Validation Suite WGUpdate for LRI Pilot WG May 1, 2012
Phase 2 Test Messages* • Anatomical Pathology/Surgical Pathology Study • Example of A4 result • Two draft messages completed (Skin biopsy and Inguinal Lymph Node biopsy) • HIV 1 Ab [Presence] • Example of Reflex testing • Draft message completed • A toxicology test • Example of Screening followed by Reflex testing • Draft Screening message for Amphetamines [Presence] in Urine with negative result completed; Reflex draft message needed • Other test messages could include urine test for Cannabinoids, Cocaine, Opiates, Phencyclidine *Will start including in Validation Tool and Test Plans in June 2012
Phase 2 Test Messages (cont’d) • Cytology Panel with four components • Example of combination of A2 and A4 results in a panel • Specimen source (identifier) in cervical or vaginal smear or scraping by Cyto stain – example of A2 result • Cytology report of cervical or vaginal smear or scraping Cyto stain thin prep – example of A4 result • Recommended follow-up (identifier) in cervical or vaginal smear or scraping by Cyto stain – example of A2 result • Cytology study comment on cervical or vaginal smear or scraping by Cyto stain – example of A4 result • Draft message needed
Phase 2 Test Messages (cont’d) • Human Genome – CFTR gene mutations found [Identifier] • Example of A3 result • Draft message completed • Complete Urinalysis (panel test) – lowest priority test • Example of A2 result • Draft message completed - to be modified using “+” or “++ “for bilirubin result value • Example of A4 results • Urine sediment comments
Needed from Pilots • Testers and feedback for current version of Validation Suite tool http://lri.sipilotdevelopment.org/lri-dstu/ • Volunteers for 1-on-1 Webex testing • Especially EHR systems • Validation Suite to be ready in June 2012
Pilot I Project Updates • Allscripts • Atlas Development • CAP • Cerner • Halfpenny Technologies • KHIE • LabLynx • RML
Value Proposition • Create value proposition statements for • Ambulatory Providers • Laboratories (does this vary by type) • Vendors • EHR • LIS • HIE • System Integrators • Value possibilities • Setup cost (each party) • Support cost (each party) • Reduced errors • Reduced TAT • Improved care delivery
Next Steps / Questions • Next Steps • Continue recruiting Pilot II partipants • Work on expanded scenarios for validation suite • Schedule • Pilot calls for coordination every other week at same time 5/1, 5/15, 5/29, … • Continue work with Validation Suite on 5/22 • Start participation in LOI and compendium effort based on LOI calendar • For questions, please feel free to contact • Bob Dieterle: rdieterle@enablecare.us